STUDY OBJECTIVES: Adenosine modulates sleep via A(1) and A(2A) receptors. As the A(1) receptor influences Ca(V)2.1 channel functioning via G-protein inhibition, there is a possible role of the Ca(V)2.1 channel in sleep regulation. To this end we investigated transgenic Cacna1a R192Q mutant mice that express mutant Ca(V)2.1 channels that are less susceptible to inhibition by G-proteins. We hypothesized that Cacna1a R192Q mice could show reduced susceptibility to adenosine, which may result in a sleep phenotype characterized by decreased sleep. DESIGN: R192Q mutant and littermate wild-type mice were subjected to a 6-h sleep deprivation, treatment with caffeine (a non-specific adenosine receptor antagonist which induces waking), or cyclopentyladenosine (CPA, an A(1) receptor specific agonist which induces sleep). MEASUREMENTS AND RESULTS: Under baseline conditions, Cacna1a R192Q mice showed more waking with longer waking episodes in the dark period and less non-rapid eye movement (NREM) sleep, but equal amounts of REM sleep compared to wild-type. After treatment with caffeine R192Q mice initiated sleep 30 min earlier than wild-type, whereas after CPA treatment, R192Q mice woke up 260 min earlier than wild-type. Both results indicate that Cacna1a R192Q mice are less susceptible to adenosinergic input, which may explain the larger amount of waking under undisturbed baseline conditions. CONCLUSION: We here show that adenosinergic sleep induction, and responses to caffeine and CPA, are modified in the R192Q mutant in a manner consistent with decreased susceptibility to inhibition by adenosine. The data suggest that the A(1) receptor modulates sleep via the Ca(V)2.1 channel.
STUDY OBJECTIVES:Adenosine modulates sleep via A(1) and A(2A) receptors. As the A(1) receptor influences Ca(V)2.1 channel functioning via G-protein inhibition, there is a possible role of the Ca(V)2.1 channel in sleep regulation. To this end we investigated transgenic Cacna1a R192Q mutant mice that express mutant Ca(V)2.1 channels that are less susceptible to inhibition by G-proteins. We hypothesized that Cacna1a R192Qmice could show reduced susceptibility to adenosine, which may result in a sleep phenotype characterized by decreased sleep. DESIGN:R192Q mutant and littermate wild-type mice were subjected to a 6-h sleep deprivation, treatment with caffeine (a non-specific adenosine receptor antagonist which induces waking), or cyclopentyladenosine (CPA, an A(1) receptor specific agonist which induces sleep). MEASUREMENTS AND RESULTS: Under baseline conditions, Cacna1a R192Qmice showed more waking with longer waking episodes in the dark period and less non-rapid eye movement (NREM) sleep, but equal amounts of REM sleep compared to wild-type. After treatment with caffeineR192Qmice initiated sleep 30 min earlier than wild-type, whereas after CPA treatment, R192Qmice woke up 260 min earlier than wild-type. Both results indicate that Cacna1a R192Qmice are less susceptible to adenosinergic input, which may explain the larger amount of waking under undisturbed baseline conditions. CONCLUSION: We here show that adenosinergic sleep induction, and responses to caffeine and CPA, are modified in the R192Q mutant in a manner consistent with decreased susceptibility to inhibition by adenosine. The data suggest that the A(1) receptor modulates sleep via the Ca(V)2.1 channel.
Authors: B B Fredholm; G Arslan; L Halldner; B Kull; G Schulte; W Wasserman Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2000-11 Impact factor: 3.000
Authors: S Kaja; R C G van de Ven; L A M Broos; H Veldman; J G van Dijk; J J G M Verschuuren; R R Frants; M D Ferrari; A M J M van den Maagdenberg; J J Plomp Journal: Neuroscience Date: 2005 Impact factor: 3.590
Authors: Ying Xu; Quasar S Padiath; Robert E Shapiro; Christopher R Jones; Susan C Wu; Noriko Saigoh; Kazumasa Saigoh; Louis J Ptácek; Ying-Hui Fu Journal: Nature Date: 2005-03-31 Impact factor: 49.962
Authors: Charles W Schindler; Marzena Karcz-Kubicha; Eric B Thorndike; Christa E Müller; Srihari R Tella; Sergi Ferré; Steven R Goldberg Journal: Br J Pharmacol Date: 2005-03 Impact factor: 8.739
Authors: Floor van Oosterhout; Stephan Michel; Tom Deboer; Thijs Houben; Rob C G van de Ven; Henk Albus; Joost Westerhout; Mariska J Vansteensel; Michel D Ferrari; Arn M J M van den Maagdenberg; Johanna H Meijer Journal: Ann Neurol Date: 2008-09 Impact factor: 10.422
Authors: Maria Panagiotou; Kostas Papagiannopoulos; Jos H T Rohling; Johanna H Meijer; Tom Deboer Journal: Front Aging Neurosci Date: 2018-08-07 Impact factor: 5.750
Authors: Elena A Korabelnikova; Alexey B Danilov; Andrey B Danilov; Yulia D Vorobyeva; Nina V Latysheva; Ada R Artemenko Journal: Pain Ther Date: 2020-07-03
Authors: Karla V Allebrandt; Maris Teder-Laving; Paola Cusumano; Goar Frishman; Rosa Levandovski; Andreas Ruepp; Maria P L Hidalgo; Rodolfo Costa; Andres Metspalu; Till Roenneberg; Cristiano De Pittà Journal: Sci Rep Date: 2017-07-04 Impact factor: 4.379